News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

HealthLinx and CytogenDx Co., Ltd to Develop New Ovarian Cancer IVD for China


9/12/2011 1:28:57 PM

September 12, 2011 -- HealthLinx, an Australian IVD company, has struck a deal with China CRO CytogenDx to seek SFDA approval for OvPlex, a HealthLinx clinical-stage diagnostic test for ovarian cancer. OvPlex measures plasma levels of anterior gradient protein 2 (AGR2), a new ovarian cancer biomarker. In a recent test, OvPlex was more accurate than CA125, the current IVD tool for ovarian cancer. More details....

Stock Symbol: (ASK: HTX)


Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES